SCHEMBL408924

SCHEMBL408924

O=C(NS(=O)(=O)Cl)OCc1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 5/20 0.67
CA2 P00918 5/20 0.67
CA12 O43570 2/20 0.67
CA9 Q16790 2/20 0.67
ALDH1A1 P00352 3/20 0.55
SMN1; SMN2 Q16637 2/20 0.53
LMNA P02545 1/20 0.53
P2RX7 Q99572 1/20 0.52
ACHE P22303 3/20 0.51
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
POLB P06746 1/20 0.50
HTT P42858 1/20 0.50
KMT2A Q03164 2/20 0.49
MAPK1 P28482 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
SLC6A2 P23975 1/20 0.49
SLC6A3 Q01959 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
MEN1 O00255 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5919563 0.86 CA1 (0.76) CA1CA2CA12CA9ALDH1A1
SCHEMBL26699284 0.84 CA1 (0.50) CA1CA2CA12CA9ALDH1A1
SCHEMBL28158752 0.84 CA1 (0.69) CA1CA2CA12CA9ALDH1A1
SCHEMBL2295789 0.83 CA12 (0.66) CA1CA2CA12CA9ALDH1A1
SCHEMBL7605430 0.83 CA1 (0.67) CA1CA2CA12CA9ALDH1A1
SCHEMBL991967 0.83 CA1 (0.67) CA1CA2CA12CA9ALDH1A1
SCHEMBL10135093 0.83 CA1 (0.71) CA1CA2CA12CA9ALDH1A1
SCHEMBL27029805 0.83 CA1 (0.67) CA1CA2CA12CA9ALDH1A1
SCHEMBL11862063 0.81 CA1 (0.65) CA1CA2CA12CA9ALDH1A1
SCHEMBL7809146 0.81 ALDH1A1 (0.62) CA1CA2CA12CA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109942600-B Preparation method of edoxaban 内蒙古京东药业有限公司 2021-08-20 CN claimed
US-12606524-B2 Synthesis of pyrrole acid derivatives Infex Therapeutics Limited (GB) 2026-04-21 US disclosed
US-12544359-B2 1-aminosulfonyl-2-carboxypyrrole derivatives as metallo-beta-lactamase inhibitors Infex Therapeutics Limited (GB) 2026-02-10 US disclosed
EP-3810615-B1 ARGINASE INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2026-01-28 EP disclosed
US-20250388571-A1 AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF BIOLEXIS THERAPEUTICS INC (US) 2025-12-25 US disclosed
EP-4608810-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS Septerna, Inc. (US) 2025-09-03 EP disclosed
CN-119100967-A 1-Aminosulfonyl-2-carboxypyrrole derivatives as metallo-beta-lactamase inhibitors 英菲克斯治疗有限公司 2024-12-10 CN disclosed
CN-114728902-B 1-Aminosulfonyl-2-carboxypyrrole derivatives as metallo-beta-lactamase inhibitors 英菲克斯治疗有限公司 2024-09-13 CN disclosed
CN-118307515-A Antibacterial compounds 英菲克斯治疗有限公司 2024-07-09 CN disclosed
WO-2024091498-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS SEPTERNA, INC. (US) 2024-05-02 WO disclosed
EP-0991412-A4 AMINOACYL SULFAMIDES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS CUBIST PHARM INC (US) 2000-06-21 EP disclosed
EP-0991412-A1 AMINOACYL SULFAMIDES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS Cubist Pharmaceuticals, Inc. (US) 2000-04-12 EP disclosed
US-5824657-A ANTICARCINOGENIC AGENTS, SKIN DISORDERS AND PSORIASIS CUBIST PHARMACEUTICALS, INC. (US) 1998-10-20 US disclosed
WO-1998041215-A1 AMINOACYL SULFAMIDES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS CUBIST PHARMACEUTICALS, INC. (US) 1998-09-24 WO disclosed
US-5726195-A Aminoacyl adenylate mimics as novel antimicrobial and antiparasitic agents CUBIST PHARMACEUTICALS, INC. (US) 1998-03-10 US disclosed
WO-1997005132-A1 AMINOACYL ADENYLATE MIMICS AS NOVEL ANTIMICROBIAL AND ANTIPARASITIC AGENTS CUBIST PHARMACEUTICALS, INC. (US) 1997-02-13 WO disclosed
US-5273993-A Antiarthritic agents; osteoporosis A. H. ROBINS COMPANY, INCORPORATED (US) 1993-12-28 US disclosed
US-5194446-A Antiarthritic agents A. H. ROBINS COMPANY, INCORPORATED (US) 1993-03-16 US disclosed
US-5192785-A Sulfamates as antiglaucoma agents A. H. ROBINS COMPANY, INCORPORATED (US) 1993-03-09 US disclosed
EP-0403185-A2 Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals A.H. ROBINS COMPANY, INCORPORATED (US) 1990-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12544359-B2 1-aminosulfonyl-2-carboxypyrrole derivatives as metallo-beta-lactamase inhibitors CBR1, CBR3, SRR CA1 745/4885CA2 78/4885CA12 409/4885
US-12606524-B2 Synthesis of pyrrole acid derivatives SRR, ME1, CD79B CA1 1236/4885CA2 414/4885CA12 1554/4885
US-20250388571-A1 AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF PRKAB2, PRKAB1, PRKAR2B CA1 3591/4885CA2 752/4885CA12 4283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.